Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium

MedGenMed Medscape General Medicine

Volumn 8, Issue 3, 2006, Pages

  Gualtieri, C Thomas ^a,b   Johnson, Lynda G ^a  

^a North Carolina Neuropsychiatry Clinics   (United States)

^b CNS Vital Signs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OXCARBAZEPINE; PSYCHOTROPIC AGENT; TOPIRAMATE; VALPROIC ACID; ANTICONVULSIVE AGENT; LITHIUM DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATTENTION DISTURBANCE; AUTOMATION; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; EPILEPSY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEMORY DISORDER; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PATIENT COMPLIANCE; PREVALENCE; PSYCHOMOTOR DISORDER; REACTION TIME; SCREENING TEST; STATISTICAL SIGNIFICANCE; VITAL SIGN; VOLUNTEER; CROSS-SECTIONAL STUDY; DRUG EFFECT; MIDDLE AGED; NERVOUS SYSTEM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADULT; AGED; ANTICONVULSANTS; BIPOLAR DISORDER; COGNITION; CROSS-SECTIONAL STUDIES; HUMANS; LITHIUM COMPOUNDS; MIDDLE AGED; NERVOUS SYSTEM; PSYCHOTROPIC DRUGS;

EID: 33748029791     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. MacLeod CM, Dekabian AS, Hunt E. Memory impairment in epileptic patients: selective effects of phenobarbital concentration. Science. 1978;202:1102-1104. Abstract
2. Meador KJ, Loring DW, Huh K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsants. Neurology. 1990;40:391-394. Abstract
3. Gualtieri CT. Brain Injury and Mental Retardation: Psychopharmacology and Neuropsychiatry. Philadelphia: Lippincott, Williams and Wilkins; 2002.
4. Gillham RA, Williams N, Wiedmann KD, Butler E, Larkin JG, Brodie MJ. Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. Epilepsy Res. 1990;7:219-225. Abstract
5. Dunn R, Frye M, Kimbrell T, Denicoff K, Leverich G, Post R. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol. 1998;21:215-235. Abstract
6. McElroy S, Keck P. Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000;48:539-557. Abstract
7. Okuma T, Kishimoto A, Inoue K. Anti-manic and prophylactic effects of carbamazepine on manic-depressive psychosis. Seishin-Igaku. 1975;17:617-630.
8. Okuma T, Inanaga K, Otsuki S. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology. 1979;66:211-217. Abstract
9. Post RM, Uhde TW, Ballenger JC. Efficacy of carbamazepine in affective disorders: implications for underlying physiological and biochemical substrates. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Elsevier Science; 1984:93-115.
10. Sachs G, Thase M. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry. 2000;48:573-581. Abstract
11. Sachs G, Printz D, Kahn D, Carpenter D, Docherty J. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med. 2000;1-104.
12. Stuppaeck C, Barnas C, Miller C, Schwitzer J, Fleishhacker WW. Carbamazepine in the prophylaxis of mood disorders. J Clin Psychopharmacol. 1990;10:39-42. Abstract
13. Winterer G, Hermann W. Valproate and the symptomatic treatment of schizophrenia spectrum patients. Pharmacopsychiatry. 2000;33:182-188. Abstract
14. Bowden CL, Swann AC, Calabrese JR, et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull. 1997;33:693-699. Abstract
15. Fatemi S, Rapport D, Calabrese J, Thuras P. Lamotrigine in rapid-cycling bipolar disorder 2649. J Clin Psychiatry. 1997;58:522-527. Abstract
16. Koller WC. Sensory symptoms in Parkinson's disease. Neurology. 1984;34:957-959. Abstract
17. Suppes T, Brown E, McElroy S, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord. 1999;53:95-98. Abstract
18. Thompson P, Huppert F, Trimble M. Anticonvulsant drugs, cognitive function and memory. Acta Neurol Scand Suppl. 1980;80:75-81. Abstract
19. Andrewes DG, Bullen JG, Tomlinson L, Elwes RD, Reynolds EH. A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia. 1986;27:128-134. Abstract
20. O'Dougherty M, Wright FS, Cox S, Walson P. Carbamazepine plasma concentration. Relationship to cognitive impairment. Arch Neurol. 1987;44:863-867. Abstract
21. Gallassi R, Morreale A, Lorusso S, Procaccianti G, Lugaresi E, Baruzzi A. Carbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal. Arch Neurol. 1988;45:892-894. Abstract
22. Prevey ML, Mattson RH, Cramer JA. Improvement in cognitive functioning and mood state after conversion to valproate monotherapy. Neurology. 1989;39:1640-1641.
23. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia. 1990;31:584-591. Abstract
24. Goldberg JF, Burdick KE. Cognitive side effects of anticonvulsants. J Clin Psychol. 2001;62:27-33.
25. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology. 2001;56:1177-1182. Abstract
26. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999;52:321-327. Abstract
27. Gualtieri CT, Johnson LG, Benedict KB. Reliability and validity of a brief computerized neurocognitive screening battery. Program and abstracts of the International Neuropsychological Society Annual Meeting; February 4, 2004; Baltimore, Maryland.
28. Gualtieri CT, Johnson LG, Benedict KB. Reliability and validity of a new computerized test battery. Program and abstracts of the International Neuropsychological Society Annual Meeting; February 4, 2004; Baltimore, Maryland.
29. Gualtieri CT, Johnson LG, Benedict KB. A computerized cognitive screening battery for psychiatrists. Program and abstracts of the American Psychiatric Association 2006 Annual Meeting; April 20, 2006; New York, NY.
30. Benedict KB, Benson J. The use of CNSVS in college students with primary attention and/or learning disorders. Program and abstracts of the 16th Annual Postsecondary Disability Training Institute (PTI); July 17, 2004; Mount Snow, Vermont.
31. Matthews CG, Harley JP. Differential psychological test performances in toxic and nontoxic adult epileptics. Neurology. 1975;25:184-188. Abstract
32. Loiseau P, Strube E, Broustet D, Buttlellochi S, Gomeni C, Morselli PL. Learning impairment in epileptic patients. Epilepsia. 1983;24:183-192. Abstract
33. Scott J, Stanton B, Garland A, Ferrier IN. Cognitive vulnerability in patients with bipolar disorder. Psychol Med. 2000;30:467-472. Abstract
34. Wilder-Willis KE, Sax KW, Rosenberg HL, Fleck DE, Shear PK, Strakowski SM. Persistent attentional dysfunction in remitted bipolar disorder. Bipolar Disord. 2001;3:58-62. Abstract
35. Basso MR, Lowery N, Neel J, Purdie R. Neuropsychological impairment among manic, depressed and mixed-episode inpatients with bipolar disorder. Neuropsychology. 2002;16:84-91. Abstract
36. Rubinsztein JS, Michael A, Paykel E, Sahakian BJ. Cognitive impairment in remission in bipolar affective disorder. Psychol Med. 2000;30:1025-1036. Abstract
37. Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology. 1991;41:141-143. Abstract
38. Dodrill CB. Problems in the assessment of cognitive effects of antiepileptic drugs. Epilepsia. 1992;33:29-32.
39. Ketter T, Post R, Theodore W. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999;53:S53-S67.
40. Aldenkamp AP, Boon PA, Deblaere K, et al. Usefulness of language and memory testing during intracarotid amobarbital testing: observations from an fMRI study. Acta Neurol Scand. 2003;108:147-152. Abstract
41. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure. 2000;9:375-379. Abstract
42. Smith D, Chadwick D, Baker G, Davis G, Dewey M. Seizure severity and the quality of life. Epilepsia. 1993;34:S31-S35.
43. Meador K, Baker G. Behavioral and cognitive effects of lamotrigine. J Child Neurol. 1997;12:S44-S47. Abstract
44. Marciani M, Stanzione P, Mattia D, et al. Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol. 1998;21:41-47. Abstract
45. Ettinger A, Weisbrot D, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia. 1998;39:874-877. Abstract
46. Mecarelli O, Vicenzini E, Pulitano P, et al. Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. Ann Pharmacother. 2004;38:1816-1822. Abstract
47. Martin R, Meador K, Turrentine L, et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia. 2001;42:764-771. Abstract
48. Tatum WOt, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia. 2001;42:1134-1140. Abstract
49. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44:339-347. Abstract
50. Dooley J, Camfield P, Smith E, Langevin P, Ronen G. Topiramate in intractable childhood onset epilepsy - a cautionary role. Can J Neurol Sci. 1999;26:271-273. Abstract
51. Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience. Seizure. 2000;9:137-141. Abstract